Cargando…

Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation

The androgen receptor (AR) signaling is a key contributor to tumorigenesis and the progression of prostate cancer. A subset of patients may develop neuroendocrine (NE) features, resulting in resistance to androgen deprivation therapy and poor prognosis. In this study, we combined immunostaining and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Ruopeng, Chen, Lei, Jiang, Zhou, Yu, Minghao, Zhang, Weiwei, Ma, Zehua, Ji, Yiyi, Shen, Kai, Xin, Zhixiang, Qi, Jun, Xue, Wei, Wang, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413533/ https://www.ncbi.nlm.nih.gov/pubmed/36033483 http://dx.doi.org/10.3389/fonc.2022.955166

Ejemplares similares

High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer
por: Chen, Lei, et al.
Publicado: (2023)

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Ma, Zehua, et al.
Publicado: (2022)

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer
por: Ji, Yiyi, et al.
Publicado: (2023)

The Evolving Role of (18)F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer
por: Shen, Kai, et al.
Publicado: (2021)

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Androgen-Targeted Therapy-Induced Epithelial Mesenchymal Plasticity and Neuroendocrine Transdifferentiation in Prostate Cancer: An Opportunity for Intervention
por: Nouri, Mannan, et al.
Publicado: (2014)

The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression
por: Terry, Stéphane, et al.
Publicado: (2014)

Prostate Cancer and Neuroendocrine Differentiation: More Neuronal, Less Endocrine?
por: Grigore, Alexandru Dan, et al.
Publicado: (2015)

Neuroendocrine Differentiation in Prostate Cancer: A Mechanism of Radioresistance and Treatment Failure
por: Hu, Chang-Deng, et al.
Publicado: (2015)

Comprehensive Analysis of Cell Cycle-Related Genes in Patients With Prostate Cancer
por: Liu, Zehua, et al.
Publicado: (2022)

A rare case of de novo large cell neuroendocrine carcinoma of the prostate with long-term survival after cystoprostatectomy and androgen deprivation
por: Miyakawa, Jimpei, et al.
Publicado: (2018)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
por: Lipianskaya, Julia, et al.
Publicado: (2014)

Clinical Landscape of Littoral Cell Angioma in the Spleen Based on a Comprehensive Analysis
por: Wang, Weijie, et al.
Publicado: (2022)

Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2022)

Enzalutamide-Induced Upregulation of PCAT6 Promotes Prostate Cancer Neuroendocrine Differentiation by Regulating miR-326/HNRNPA2B1 Axis
por: Liu, Bo, et al.
Publicado: (2021)

Pancreatic metastasis from locally recurrent neuroendocrine differentiated prostate cancer after radical prostatectomy
por: Ando, Takashi, et al.
Publicado: (2020)

The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
por: Aragon-Ching, Jeanny B.
Publicado: (2014)

JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer
por: Pawar, Jogendra Singh, et al.
Publicado: (2023)

Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2023)

SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis
por: Shangguan, Xun, et al.
Publicado: (2021)

Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2015)

Primary neuroendocrine prostate cancer with adrenal gland metastasis
por: Muñoz López, Antonio Yaromin, et al.
Publicado: (2021)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Ceramide Regulates Anti-Tumor Mechanisms of Erianin in Androgen-Sensitive and Castration-Resistant Prostate Cancers
por: Trapika, I Gusti Md Gde Surya C., et al.
Publicado: (2021)

Comprehensive analysis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs): A SEER database analysis of 767 cases
por: Song, Huixin, et al.
Publicado: (2023)

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation
por: Bergamini, Marco, et al.
Publicado: (2022)

Human SP-D Acts as an Innate Immune Surveillance Molecule Against Androgen-Responsive and Androgen-Resistant Prostate Cancer Cells
por: Thakur, Gargi, et al.
Publicado: (2019)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

A Testosterone Metabolite 19-Hydroxyandrostenedione Induces Neuroendocrine Trans-Differentiation of Prostate Cancer Cells via an Ectopic Olfactory Receptor
por: Abaffy, Tatjana, et al.
Publicado: (2018)

Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications
por: Ma, Zehua, et al.
Publicado: (2021)

Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression
por: Wang, Zheng, et al.
Publicado: (2020)

A rare case of prostate neuroendocrine tumor: A case report
por: Teh, Shunxing, et al.
Publicado: (2022)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
por: Huang, Jian, et al.
Publicado: (2022)

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
por: Yoshida, Tsukasa, et al.
Publicado: (2022)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Landscape of Carbon Ion Radiotherapy in Prostate Cancer: Clinical Application and Translational Research
por: Chen, Xue, et al.
Publicado: (2021)

Genetically predicted iron status was associated with the risk of prostate cancer
por: Ying, Jiacheng, et al.
Publicado: (2022)

Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers
por: Zhang, Yan, et al.
Publicado: (2018)

Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report
por: Hara, Midori, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i1s996musm6v0nbib4e93sganf